Get started
Author

Tatiana Hernández‐Guerrero

Observed names: Hernandez-Guerrero, T., T. Hernandez-Guerrero, T. Hernández Guerrero, T. Hernández-Guerrero, Tatiana Hernandez, Tatiana Hernandez Guerrero, Tatiana Hernandez-Guerrero, Tatiana Hernández, Tatiana Hernández Guerrero, Tatiana Hernández-Guerrero
Institution: Delfos Hospital
ORCID: 0000-0003-3459-871X
Observed ORCID: 0000-0003-3459-871X
OpenAlex ID: A5056008207
MYC targeting by OMO-103 in solid tumors: a phase 1 trial
2024 · Elena Garralda, Marie-Eve Beaulieu, et al. · Nature Medicine · 225
PDF
Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
2023 · Maria Vieito, Victor Moreno, et al. · Clinical Cancer Research · 108
A first-in-human study of the fibroblast activation protein–targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors
2023 · Ignacio Melero, Tamara Tanos, et al. · Science Translational Medicine · 89
Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma
2020 · V. Moreno, J.M. Sepulveda, et al. · Annals of Oncology · 71
PDF
BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas
2023 · Victor Moreno, Maria Vieito, et al. · Nature Communications · 27
PDF
First-in-human phase I/II trial evaluating BNT142, a first-in-class mRNA encoded, bispecific antibody targeting Claudin 6 (CLDN6) and CD3, in patients (pts) with CLDN6-positive advanced solid tumors.
2025 · Timothy A. Yap, Alberto Hernando Hernando-Calvo, et al. · Journal of Clinical Oncology · 18
PDF
Increased vulnerability of clinical research units during the COVID‐19 crisis and their protection
2020 · Maria de Miguel, Bernard Doger, et al. · Cancer · 13
PDF
GITR Antibodies in Cancer: Not Ready for Prime Time
2022 · Tatiana Hernandez-Guerrero, Victor Moreno · Clinical Cancer Research · 12
Dose escalation study of OMO-103, a first in class Pan-MYC-Inhibitor in patients (pts) with advanced solid tumors
2022 · E. Garralda, V. Moreno, et al. · European Journal of Cancer · 10
PDF
INDUCE-1: Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5-FU chemotherapy (5-FU/plat), with or without pembrolizumab (PE), for the treatment of advanced solid tumors.
2020 · Erminia Massarelli, Ani Sarkis Balmanoukian, et al. · Journal of Clinical Oncology · 10
Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma
2019 · Hernandez-Guerrero, T., Doger, B., et al. · Drugs of today · 8
A phase 1b, open-label, single-arm study of cofetuzumab pelidotin (a PTK7-targeting antibody-drug conjugate) in patients with PTK7-expressing, recurrent non-small cell lung cancer (NSCLC).
2021 · Eric S. Schaefer, D. Ross Camidge, et al. · Journal of Clinical Oncology · 7
A phase 1/2 trial of lurbinectedin (L) in combination with pembrolizumab (P) in relapsed small cell lung cancer (SCLC): The LUPER study.
2022 · Antonio Calles, Alejandro Navarro, et al. · Journal of Clinical Oncology · 6
Derivation and External Validation of Objective Performance Status Among Patients With Metastatic Cancer
2025 · Eva Ruiz, Christopher R. Manz, et al. · JCO Oncology Practice · 5
Abstract PS7-02: First-in-human results of STX-478, a mutant-selective PI3K alpha inhibitor, in HR+ breast cancer and advanced solid tumor patients
2025 · Dejan Juric, Antonio Giordano, et al. · Clinical Cancer Research · 5
Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug–Drug Interaction Study
2024 · Irene Moreno, Tatiana Hernández, et al. · Marine Drugs · 5
PDF
16O Phase I study of CC-90010, a reversible, oral BET inhibitor in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)
2020 · V. Moreno, I. Braña, et al. · Annals of Oncology · 4
PDF
EMITT-1: Clinical and pharmacodynamic activity with the oral ERAP1 inhibitor GRWD5769 and cemiplimab in 6 completed phase 1b expansion cohorts in solid tumors with anti–PD-1 resistance or MSS-CRC.
2026 · Fiona Thistlethwaite, Desamparados Roda, et al. · Journal of Clinical Oncology · 3
PDF
First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6–Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non–Small Cell Lung Cancer
2026 · Solange Peters, Sarina A. Piha-Paul, et al. · Journal of Clinical Oncology · 3
PDF
EMITT-1: Proof-of-mechanism immunopeptidome (ImPD) effects at target PK exposure, in a phase 1 study of GRWD5769 (a first-in-class inhibitor of Endoplasmic Reticulum Aminopeptidase 1 [ERAP1]) in patients with solid malignancies.
2024 · Thomas Lillie, Ganessan Kichenadasse, et al. · Journal of Clinical Oncology · 3
Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug–Drug Interaction Study
2024 · Irene Moreno, Tatiana Hernández, et al. · Pharmaceuticals · 3
PDF
Patient Characteristics Associated with Growth of Patient-Derived Tumor Implants in Mice (Patient-Derived Xenografts)
2023 · Tatiana Hernández Guerrero, Natalia Baños, et al. · Cancers · 3
PDF
Prolonged survival in a patient with pbrm1 mutated metastatic cholangiocarcinoma receiving tazemetostat
2025 · Manuel Pedregal, Esther Cabañas Morafraile, et al. · npj Precision Oncology · 2
PDF
A phase 2 safety and efficacy study of PRT3789 in combination with pembrolizumab in patients with advanced or metastatic solid tumors and a SMARCA4 mutation.
2025 · Timothy A. Yap, Martin Gutierrez, et al. · Journal of Clinical Oncology · 2
PDF
Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer
2025 · Harveer Dev, Mark Linch, et al. · Clinical Cancer Research · 2
Works count: 69
Citation count: 652
H-index: 10
I10-index: 10
Year
Topic
Type